Changes in Bacterial Mix Linked to Antibiotics Increase Risk for Type 1 Diabetes in Animal Model

News provided by

Jul 24, 2018, 11:55 ET

NEW YORK, July 24, 2018 /PRNewswire/ -- A single course of antibiotics early in childhood may increase risk for Type 1 diabetes. This is the finding of a study in mice led by researchers from NYU Medical School and published online July 24 in the journal eLife.

The study centered on the intestinal microbiome, the mix of bacterial species that live in the digestive tract, and that co-evolved with humans to play roles in nutrition and immunity. As rates of children's exposure to antibiotics has increased in recent decades – with each child receiving nearly three courses on average in the first two years of life – the number of patients with type 1 diabetes has doubled, say the study authors.

In prior work, and using mice that have an unusually high rate of type 1 diabetes, the research team had found that exposure to multiple courses of antibiotics accelerated onset of this disease. The current study finds that even a single antibiotic course significantly increased risk and severity.

The normal mix of inherited microbes is thought to "educate" the founding immune system, with evolution choosing microbes that decrease the sensitivity of immune cells, making them less likely to mistakenly attack the body's own cells, say the authors. In autoimmune diseases like type 1 diabetes, immune cells that normally control invading microbes instead destroy insulin-producing cells in the pancreas.

Patients with type 1 diabetes produce little or no insulin, the hormone that controls the level of sugar in the blood. In the current study, the onset of disease was determined by measuring blood sugar, and by marking when levels rose to extremely high levels due to the lack of insulin.

"Our findings confirm earlier work showing that antibiotics can increase risk for type 1 diabetes," says lead study author Xuesong Zhang, PhD, assistant professor of Medicine at NYU School of Medicine. "Even a single early life course may perturb the intestinal microbiome in ways that lead to long-term consequences in the intestinal wall, including immune cell changes and damage to the pancreas."

Senior study investigator Martin Blaser, M.D., director of the Human Microbiome Program at NYU School of Medicine, said the results "are a model of the pervasive effects that antibiotic courses may have on children, causing immune systems to develop abnormally on the way to serious illness."

The research team used genomic and statistical techniques to analyze the millions of pieces of bacterial DNA in samples taken from the study mice. Past studies had already matched key DNA sequences to known bacterial species, enabling the team to define each mouse's microbiome, and to watch the effect of antibiotics on each.

Specifically, the study found that four bacterial species groups (taxa) – Enterococcus, Blautia, Enterobacteriaceae, and Akkermansia – were significantly more abundant in the guts of mice treated with the single course of antibiotics, and likely involved in driving progression of type 1 diabetes. While normally harmless, such species, called pathobionts, cause disease when environmental factors like antibiotics alter the normal balance. Past studies had found that human children who later developed type 1 diabetes were more likely to have had altered gut microbiota representation of Blautia and Akkermansia mucinophila early in life, with corresponding changes to their immune systems.

The shift in dominant species seen with antibiotics was accompanied by a shift in active bacterial genes and in chemical compounds produced by the bacteria. This in turn caused changes in gene expression patterns in the intestinal wall, say the authors. Many of these genes are known to influence the type of immune cell activation that damages pancreatic islets.

In addition, populations of four different taxa – S24-7, Clostridiales, Oscillospira, and Ruminococcus – were significantly smaller in mice treated with antibiotics in comparisons with normal mice during the developmental post-birth time window previously shown to be critical to educating the immune system. The results suggest that these taxa may be protective against Type 1 diabetes, and could be a focus of future development of probiotics, for instance, that seek to restore healthy species in newborns.

The current study focused on male mice simply because it examined mechanisms found to be important in the autoimmune development regardless of gender.

The authors say their findings support the hypothesis that, by diminishing particular beneficial bacteria, one early exposure to antibiotics permits the emergence of other species that change immunological development and worsen pancreatic damage.

***

Along with Blaser and Zhang, study authors from the NYU School of Medicine departments of Medicine and Microbiology were Jackie Li, Michelle Badri, Thomas Battaglia, Timothy Borbet, Sandy Ng, Rachel Sibley, Shawn Jindal, Victoria Ruiz, Alexandra Livanos, and Kelly Ruggles. Other NYU authors were Hyunwook Koh and Huilin Li from the Department of Population Health at NYU School of Medicine, as well as Richard Bonneau of New York University's Center for Data Science.

Authors from other institutions were Kimberly Krautkramer and John Denu from the Department of Biomolecular Chemistry at the University of Wisconsin School of Medicine and Public Health; Yuanyuan Li, Wimal Pathmasiri. and Susan Jenkins Sumner of the Nutrition Research Institute at the University of North Carolina at Chapel Hill School of Public Health; Robin Shields-Cutler, Ben Hillmann, Gabriel Al-Ghalith, and Dan Knights of the BioTechnology Institute, Computer Science and Engineering, University of Minnesota, St. Paul; Arlin Rogers Department of Biomedical Sciences, Cummings School of Veterinary Medicine, Tufts University, and Angelique Wout, Nabeetha Nagalingam, Anthony Williamson, and Marcus Rauch of the Janssen Prevention Center London, London, UK.

This study was supported by National Institute of Health grants 5T35DK007421, R37GM059785, F30 DK108494, T32GM008692, and R01DK110014, as well as by Janssen Labs London (15-A0-00-00-0039-29-01), the TransAtlantic Networks of Excellence Program of Fondation Leducq, and by the C & D fund.

Contact:
Gregory Williams
212-404-3533
[email protected]

SOURCE NYU Langone Health